Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Jacques Body

Showing results (51-60 of 133) with videos related to

Pageof 14
Sort By:
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 7, 2020
Postfracture Risk Assessment: Target the Centrally Sited Fractures First! A Substudy of NoFRACTVirginie Kinnard, Felicia Baleanu, Laura Iconaru, et al.
Journal of Bone Oncology|May 5, 2021
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancerKomal Waqas, Joana Lima Ferreira, Elena Tsourdi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 6, 2009
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJean-Jacques Body, Allan Lipton, Julie Gralow, et al.
Bone|October 24, 2021
Bariatric surgery and skeletal health: A narrative review and position statement for management by the European Calcified Tissue Society (ECTS)Julien Paccou, Elena Tsourdi, Christian Meier, et al.
BMC Cancer|January 9, 2025
Editorial Expression of Concern: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsHichame Id Boufker, Laurence Lagneaux, Mehdi Najar, et al.
BMC Cancer|June 23, 2010
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsHichame Id Boufker, Laurence Lagneaux, Mehdi Najar, et al.
Bone|October 27, 2019
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trialDavid L Kendler, Fernando Marin, Piet Geusens, et al.
The Journal of Rheumatology|August 4, 2005
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronatePaul D Miller, William J Shergy, Jean-Jacques Body, et al.
Maturitas|August 26, 2017
Skeletal health in breast cancer survivorsOlivier Bruyère, Pierre Bergmann, Etienne Cavalier, et al.
Maturitas|February 19, 2003
Response to alendronate in osteoporotic women previously treated with pamidronateAnne Peretz, Vania Siderova, Jean Jacques Body, et al.
Pageof 14

Showing results (51-60 of 133) with videos related to

Sort By:
Pageof 14
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 7, 2020
Postfracture Risk Assessment: Target the Centrally Sited Fractures First! A Substudy of NoFRACTVirginie Kinnard, Felicia Baleanu, Laura Iconaru, et al.
Journal of Bone Oncology|May 5, 2021
Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancerKomal Waqas, Joana Lima Ferreira, Elena Tsourdi, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 6, 2009
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposureJean-Jacques Body, Allan Lipton, Julie Gralow, et al.
Bone|October 24, 2021
Bariatric surgery and skeletal health: A narrative review and position statement for management by the European Calcified Tissue Society (ECTS)Julien Paccou, Elena Tsourdi, Christian Meier, et al.
BMC Cancer|January 9, 2025
Editorial Expression of Concern: The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsHichame Id Boufker, Laurence Lagneaux, Mehdi Najar, et al.
BMC Cancer|June 23, 2010
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblastsHichame Id Boufker, Laurence Lagneaux, Mehdi Najar, et al.
Bone|October 27, 2019
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trialDavid L Kendler, Fernando Marin, Piet Geusens, et al.
The Journal of Rheumatology|August 4, 2005
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronatePaul D Miller, William J Shergy, Jean-Jacques Body, et al.
Maturitas|August 26, 2017
Skeletal health in breast cancer survivorsOlivier Bruyère, Pierre Bergmann, Etienne Cavalier, et al.
Maturitas|February 19, 2003
Response to alendronate in osteoporotic women previously treated with pamidronateAnne Peretz, Vania Siderova, Jean Jacques Body, et al.
Pageof 14